Spatial Repellents for Vector Control (NCT04795648) | Clinical Trial Compass
CompletedNot Applicable
Spatial Repellents for Vector Control
Mali1,911 participantsStarted 2021-07-08
Plain-language summary
The primary objective of the study is to demonstrate and quantify the protective efficacy of a single Spatial Repellent (SR) product, in reducing malaria infection in a human cohort. The study design will be a prospective cluster Randomized Control Trial (cRCT).
Who can participate
Age range6 Months – 10 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children ≥ 6 months to \< 10 years of age
* Children with Hb \> 7 g/dL and no signs of known chronic disease or other other serious illness
* Sleeps in cluster ≥ 90% of nights during any given month
* Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
* Provision of informed consent (and/or assent) form (ICF) signed by the parent(s) or guardian
Exclusion Criteria:
* Children \< 6 months or ≥ 10 years
* Childrend with Hb \<= 7 g/dL with signs of known chronic disease or other serious illness, or Hb \<6 g/dL with signs of clinical decompensation
* Sleeps in cluster \<90% of nights during any given month
* Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial
* No provision of ICF (and/or assent) signed by the parent(s) or guardian
What they're measuring
1
Number of first-time malaria infections during intervention period.